UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 000-55167 PetVivo Holdings, Inc. Securities registered under Section 12(g) of the Act: (Exact name of registrant as speci ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q3 2022 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer and President Robert Folkes - Chief Financial Officer Conference Call Participants Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corres ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 000-55167 PetVivo Holdings Inc. (Name of small business issuer in its charter) (State or other jurisdiction of incorporation or or ...

Financial Data and Key Metrics Changes - The company raised approximately $11.25 million through a registered public offering, which closed on August 13, 2021 [5] - As of September 30, the company ended the quarter with over $8.8 million in cash [10] - The most significant event was raising approximately $9.8 million in net proceeds from the registered offering [9] Business Line Data and Key Metrics Changes - The company rebranded its key product for treating osteoarthritis from "Kush" to "Spryng" to avoid associations with cannabis products [5][13] - The company is focusing on expanding sales and marketing efforts to gain veterinary acceptance and generate revenue from Spryng [10] Market Data and Key Metrics Changes - The company plans to attend approximately 19 trade shows, primarily focused on equine products, with the largest show being VMX in Orlando [14] - The company has started launching commercials targeting consumers on major networks such as CNN, MSNBC, and Fox [15] Company Strategy and Development Direction - The company aims to hire six to eight additional salespeople over the next 12 months to enhance its sales force [13] - The strategy includes expanding sales channels through partnerships and conducting additional studies beyond the Colorado state study for both equine and canine markets [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the numbers being within the expected range during roadshows for the offering [20] - The company is focused on educating the market about its product and driving consumer interest through various marketing strategies [15] Other Important Information - Key hires were made to strengthen the management team, including a Chief Operating Officer and a National Director of Sales with extensive veterinary sales experience [6][7] - The company engaged an advertising agency to assist with marketing efforts [11] Q&A Session Summary - No questions were raised during the Q&A session, and management expressed surprise at the lack of inquiries [18][20]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The financial statements for the period ended September 30, 2021, show significant improvement in financial position due to a public offering, increasing assets and equity while reducing net loss [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet significantly strengthened by September 30, 2021, with total assets increasing to **$9.9 million** and equity turning positive Condensed Consolidated Balance Sheet Highlights (Unaudited) | Financial Metric | September 30, 2021 | March 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $8,817,472 | $23,578 | | Total Current Assets | $9,510,922 | $147,153 | | Total Assets | $9,914,124 | $835,247 | | **Liabilities & Equity** | | | | Total Current Liabilities | $1,217,733 | $1,405,048 | | Total Liabilities | $1,365,870 | $1,732,226 | | Total Stockholders' Equity (Deficit) | $8,548,254 | $(896,979) | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net loss decreased for both three and six-month periods ended September 30, 2021, primarily due to the absence of derivative expenses Statement of Operations Summary (Unaudited) | Metric | Three Months Ended Sep 30, 2021 | Three Months Ended Sep 30, 2020 | Six Months Ended Sep 30, 2021 | Six Months Ended Sep 30, 2020 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $4,977 | $4,790 | $9,122 | $6,797 | | Total Operating Expenses | $1,108,333 | $823,007 | $1,625,946 | $1,267,082 | | Operating Loss | $(1,103,356) | $(818,567) | $(1,621,875) | $(1,260,635) | | Derivative Expense | $0 | $(389,300) | $0 | $(731,500) | | Net Loss | $(1,105,474) | $(1,348,002) | $(1,596,103) | $(2,162,010) | | Net Loss Per Share | $(0.13) | $(0.23) | $(0.21) | $(0.37) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by financing activities significantly increased cash by **$8.8 million** for the six months ended September 30, 2021 Cash Flow Summary for Six Months Ended September 30 (Unaudited) | Cash Flow Activity | 2021 | 2020 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | $(1,340,137) | $(472,307) | | Net Cash Used in Investing Activities | $(36,213) | $(107,991) | | Net Cash Provided by Financing Activities | $10,170,244 | $735,459 | | **Net Increase in Cash** | **$8,793,894** | **$155,161** | - The primary source of financing cash flow in the six months ended September 30, 2021, was **$10.2 million** from the sale of stock and warrants[20](index=20&type=chunk) [Notes to Financial Statements](index=10&type=section&id=Notes%20to%20Financial%20Statements) Notes detail accounting policies, a **1-for-4** reverse stock split, and the August 2021 public offering that raised **$9.78 million** to address going concern - The company effectuated a **1-for-4 reverse stock split** of its common stock on December 29, 2020[25](index=25&type=chunk) - In August 2021, the company raised net proceeds of approximately **$9.78 million** from a public offering, addressing previous 'going concern' doubts for the next twelve months[87](index=87&type=chunk) - On August 13, 2021, the company sold **2.5 million units** at **$4.50 per unit** in a public offering, each unit consisting of one share of common stock and one warrant[97](index=97&type=chunk) - In November 2021, the company received a letter alleging breach of settlement and consulting agreements from a former officer, which the company believes is without material impact[116](index=116&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the launch of Spryng™ and improved liquidity from the August 2021 public offering, which raised **$9.78 million**, reducing net loss [Current Business Operations](index=26&type=section&id=Current%20Business%20Operations) The company launched Spryng™ in September 2021, targeting a **$4 billion** canine osteoarthritis market and **$550 million** equine lameness market - The company's lead product, **Spryng™**, was launched in September 2021 for treating osteoarthritis and lameness in dogs and horses[121](index=121&type=chunk) - The estimated market opportunity for canine osteoarthritis is **$4 billion**, affecting approximately **14 million** dogs in the US and EU[124](index=124&type=chunk) - Commercialization in the U.S. will leverage major veterinary-product distributors, supported by regional sales representatives and digital marketing[132](index=132&type=chunk)[133](index=133&type=chunk) [Results of Operations](index=28&type=section&id=Results%20of%20Operations) Net loss decreased for both three and six-month periods ended September 30, 2021, primarily due to the absence of derivative expenses Comparison of Results for the Three Months Ended September 30 | Metric | 2021 | 2020 | | :--- | :--- | :--- | | Revenues | $4,977 | $4,790 | | Operating Expenses | $1,108,333 | $823,007 | | Other Expense | $2,118 | $529,435 | | Net Loss | $(1,105,474) | $(1,348,002) | Comparison of Results for the Six Months Ended September 30 | Metric | 2021 | 2020 | | :--- | :--- | :--- | | Revenues | $9,122 | $6,797 | | Operating Expenses | $1,625,946 | $1,267,082 | | Other Income (Expense) | $25,772 | $(901,375) | | Net Loss | $(1,596,103) | $(2,162,010) | - The decrease in net loss for both periods was primarily due to the absence of derivative expenses recognized in 2020[143](index=143&type=chunk)[150](index=150&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity significantly improved with **$9.78 million** net proceeds from the August 2021 public offering, providing sufficient capital for the next 12 months - On August 13, 2021, the company closed a public offering with net proceeds of approximately **$9,781,000**[151](index=151&type=chunk) Liquidity Position as of September 30, 2021 | Metric | Amount | | :--- | :--- | | Current Assets | $9,510,922 | | Cash | $8,817,472 | | Current Liabilities | $1,217,733 | | Working Capital | $8,293,189 | - Management believes the current working capital is sufficient to fund operations for at least the next 12 months[152](index=152&type=chunk)[161](index=161&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Disclosure for market risk is not required for smaller reporting companies - Disclosure is not required for this item[164](index=164&type=chunk) [Item 4. Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were not effective as of September 30, 2021, with no significant changes to internal controls - As of September 30, 2021, disclosure controls and procedures were concluded to be **not effective** by the principal executive and financial officers[166](index=166&type=chunk) - No significant changes occurred in internal control over financial reporting during the quarter ended September 30, 2021[167](index=167&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ordinary course legal claims, none of which are expected to materially impact its financial position or operations - The company does not expect current legal proceedings to have a **material impact** on its financial position, cash flows, or operations[168](index=168&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued **432,230** unregistered shares and used **$101,400** of the **$9.78 million** public offering proceeds for debt repayment - From April to September 2021, the company issued **432,230 shares** of common stock through unregistered sales for cash, debt conversion, warrant exercises, and services[169](index=169&type=chunk)[170](index=170&type=chunk) - The August 2021 Public Offering raised net proceeds of approximately **$9,781,000**[173](index=173&type=chunk) - A portion of the public offering proceeds, **$101,400**, was used for debt repayment to the CEO, directors, and a former director[174](index=174&type=chunk) [Item 3. Defaults Upon Senior Securities](index=33&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) Disclosure for defaults upon senior securities is not required for this item - Disclosure is not required for this item[176](index=176&type=chunk) [Item 4. Mine Safety Disclosure](index=33&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) Disclosure for mine safety is not required for this item - Disclosure is not required for this item[177](index=177&type=chunk) [Item 5. Other information](index=33&type=section&id=Item%205.%20Other%20information) No other information was reported for this period - None[178](index=178&type=chunk) [Item 6. Exhibits](index=34&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Quarterly Report, including agreements and officer certifications - The report includes exhibits such as the Underwriting Agreement, Warrant Agent Agreement, and certifications from the Principal Executive Officer and Principal Financial Officer[180](index=180&type=chunk)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 000-55167 PetVivo Holdings Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 000-55167 PetVivo Holdings, Inc. (Exact name of registrant as specified in its charter) | | | (State or other jurisdi ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 5251 Edina Industrial Blvd. Edina, Minnesota 55439 (Address of principal executive offices) For the quarterly period ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 000-55167 PetVivo Holdings Inc. (N ...